Theriva Biologics Stock Forecast

Stock Price Forecast

The 1 analyst with a 12-month price forecast for Theriva Biologics stock has a target of 1.00, which predicts an increase of 179.80% from the current stock price of 0.36.

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$1.00	$1.00	$1.00	$1.00
Change	+179.80%	+179.80%	+179.80%	+179.80%

Analyst Ratings

According to 1 stock analyst, the rating for Theriva Biologics is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Feb '26	Mar '26	Apr '26
Strong Buy	0	1	1
Buy	0	0	0
Hold	1	0	0
Sell	0	0	0
Strong Sell	0	0	0
Total	1	1	1

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Jason McCarthy Maxim Group	Maxim Group	Hold → Strong Buy Upgrades $1	Hold → Strong Buy	Upgrades	$1	+179.80%	Mar 31, 2026
Jason McCarthy Maxim Group	Maxim Group	Strong Buy → Hold Downgrades n/a	Strong Buy → Hold	Downgrades	n/a	n/a	May 8, 2025
Jason McCarthy Maxim Group	Maxim Group	Strong Buy Maintains $25 → $6	Strong Buy	Maintains	$25 → $6	+1,578.79%	Nov 13, 2024

More Analyst Ratings

Financial Forecast

Revenue This Year

n/a

Revenue Next Year

n/a

EPS This Year

-0.20

from -2.08

EPS Next Year

-0.20

from -0.20

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	-	-	-	-	-	-	-
Revenue Growth	-	-	-	-	-	-	-
EPS	-47.57	-32.66	-28.48	-19.03	-2.08	-0.20	-0.20
EPS Growth	-	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-	-
No. Analysts	-	-	-	-	-	4	4

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2026	2027
High	n/a	n/a
Avg	n/a	n/a
Low	n/a	n/a

Revenue Growth

Revenue Growth	2026	2027
High	-	-
Avg	-	-
Low	-	-

EPS Forecast

EPS	2026	2027
High	-0.21	-0.21
Avg	-0.20	-0.20
Low	-0.20	-0.20

EPS Growth

EPS Growth	2026	2027
High	-	-
Avg	-	-
Low	-	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.